Sangamo Therapeutics, Inc. announced dosing of the first patient in the Phase I/II STEADFAST clinical study evaluating TX200, a wholly-owned autologous CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.
[Sangamo Therapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.
